메뉴 건너뛰기




Volumn 18, Issue 2, 2004, Pages 98-101

Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection

Author keywords

Alendronate; Bisphosphonates; Fluorescamine derivatives; Pharmacokinetic study

Indexed keywords

BLOOD; BONE; CALCIUM PHOSPHATE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PARTICLE SIZE;

EID: 1842555447     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.298     Document Type: Article
Times cited : (33)

References (6)
  • 2
    • 0024519792 scopus 로고
    • Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection
    • Flesch G and Hauffe SA. Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. Journal of Chromatography 1989; 489: 446-451.
    • (1989) Journal of Chromatography , vol.489 , pp. 446-451
    • Flesch, G.1    Hauffe, S.A.2
  • 3
    • 0025760537 scopus 로고
    • Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by precolumn derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection
    • Flesch G, Tominaga N and Degen P. Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by precolumn derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. Journal of Chromatography 1991; 568: 261-266.
    • (1991) Journal of Chromatography , vol.568 , pp. 261-266
    • Flesch, G.1    Tominaga, N.2    Degen, P.3
  • 4
    • 0029801731 scopus 로고    scopus 로고
    • Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis
    • Hodsman A, Adachi J and Olszynski W. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis. Canadian Medical Association Journal 1996; 155: 945-948.
    • (1996) Canadian Medical Association Journal , vol.155 , pp. 945-948
    • Hodsman, A.1    Adachi, J.2    Olszynski, W.3
  • 5
    • 0030766898 scopus 로고    scopus 로고
    • Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy
    • Skingle SJ, Moore DJ and Crisp AJ. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. International Journal of Clinical Practice 1997; 51: 364-367.
    • (1997) International Journal of Clinical Practice , vol.51 , pp. 364-367
    • Skingle, S.J.1    Moore, D.J.2    Crisp, A.J.3
  • 6
    • 0030826271 scopus 로고    scopus 로고
    • How do bisphosphonates prevent fractures?
    • Tobias JH. How do bisphosphonates prevent fractures? Annals of Rheumatic Disease 1997; 56: 510-511.
    • (1997) Annals of Rheumatic Disease , vol.56 , pp. 510-511
    • Tobias, J.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.